Game-Changer for HIV: Dr Reddy’s, Hetero to Sell Generic Lenacapavir at Rs 3,547 a Year We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
GENEVA: Generic versions of a groundbreaking injectable HIV-prevention drug will be available for $40 a year in over 100 countries starting in 2027, Unitaid and the Gates Foundation announced Wednesday. The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir – a twice-yearly injection shown to reduce the…
Lupin gets tentative USFDA nod for HIV drug We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Gilead Sciences, the largest maker of HIV medicines, is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs. And the move is adding to financial uncertainty for the programs on top of concerns prompted by Trump administration funding cuts. The company recently told the state programs…
Gilead Sciences gets European Commission marketing authorization for twice yearly Yeytuo for HIV prevention We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Gilead Company Kite to buy Interius BioTherapeutics for USD 350 million We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source…